Neoadjuvant Chemotherapy Versus Debulking Surgery in Advanced Tubo-Ovarian Cancers: Pooled Analysis of Individual Patient Data From the EORTC 55971 and CHORUS Trials. Issue 3 (March 2019)

• Record Type: Journal Article
• Authors: Vergote, Ignace; Coens, Corneel; Nankivell, Matthew; Kristensen, Gunnar B.; Parmar, Mahesh K. B.; Ehlen, Tom; Jayson, Gordon C.; Johnson, Nick; Swart, Ann Marie; Verheijen, René; McCluggage, W. Glenn; Perren, Tim; Panici, Pierluigi Benedetti; Kenter, Gemma; Casado, Antonio; Mendiola, Cesar; Stuart, Gavin; Reed, Nick S.; Kehoe, Sean
• Is Part Of: Obstetrical & gynecological survey. Volume 74:Issue 3(2019)
• Publication Date: 2019-03
• Subjects: Obstetrics -- Periodicals; Gynecology -- Periodicals; Generative organs, Female -- Surgery -- Periodicals; 618
• DOI: 10.1097/01.ogx.0000554460.78765.59
• Languages: English
• ISSNs: 0029-7828

Abstract

Abstract : (Abstracted from Lancet Oncol 2018;19:1680–1687) Most women with carcinoma of the ovary, fallopian tube, or peritoneum (tubo-ovarian cancer) present with advanced disease and have a very poor prognosis. An essential therapeutic strategy in these women has been primary debulking surgery (PDS), but no randomized controlled trials have demonstrated an improved prognosis of patients with this strategy.